Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Marijke Linschoten, Janine A. M. Kamphuis, Anna van Rhenen, Laurens P. Bosman, Maarten J. Cramer, Pieter A. Doevendans, Arco J. Teske, Folkert W. Asselbergs
Topics & Concepts
MedicineRituximabCHOPPrednisoneVincristineMeta-analysisInternal medicineCyclophosphamideAdverse effectOncologyLymphomaDoxorubicinChemotherapyCardiac tumors and thrombiChemotherapy-induced cardiotoxicity and mitigationLymphoma Diagnosis and Treatment